Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics
March 07, 2020 at 13:24 PM EST
Abpro Bio, a Korean company, announced a $1.1 billion agreement to acquire Asian rights (including China) to two bispecific antibody candidates being developed by Abpro of Boston.
